Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Phosphorodiamidates as a promising new phosphate prodrug motif for antiviral drug discovery: application to anti-HCV agents

McGuigan, Christopher ORCID: https://orcid.org/0000-0001-8409-710X, Madela, Karolina, Aljarah, Mohamed, Bourdin, Claire, Arrica, Maria, Barrett, Emma, Jones, Sarah Louise, Kolykhalov, Alexander, Bleiman, Blair, Bryant, K. Dawn, Ganguly, Babita, Gorovits, Elena, Henson, Geoffrey, Hunley, Damound, Hutchins, Jeff, Muhammad, Jerry, Obikhod, Aleksandr, Patti, Joseph, Walters, C. Robin, Wang, Jin, Vernachio, John, Ramamurty, Changalvala V. S., Battina, Srinivas K. and Chamberlain, Stanley 2011. Phosphorodiamidates as a promising new phosphate prodrug motif for antiviral drug discovery: application to anti-HCV agents. Journal of Medicinal Chemistry 54 (24) , pp. 8632-8645. 10.1021/jm2011673

Full text not available from this repository.

Abstract

We herein report phosphorodiamidates as a significant new phosphate prodrug motif. Sixty-seven phosphorodiamidates are reported of two 6-O-alkyl 2′-C-methyl guanosines, with significant variation in the diamidate structure. Both symmetrical and asymmetric phosphorodiamidates are reported, derived from various esterified amino acids, both d and l, and also from various simple amines. All of the compounds were evaluated versus hepatitis C virus in replicon assay, and nanomolar activity levels were observed. Many compounds were noncytotoxic at 100 μM, leading to high antiviral selectivities. The agents are stable in acidic, neutral, and moderately basic media and in selected biological media but show efficient processing by carboxypeptidases and efficiently yield the free nucleoside monophosphate in cells. On the basis of in vitro data, eight leads were selected for additional in vivo evaluation, with the intent of selecting one candidate for progression toward clinical studies. This phosphorodiamidate prodrug method may have broad application outside of HCV and antivirals as it offers many of the advantages of phosphoramidate ProTides but without the chirality issues present in most cases.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Pharmacy
Systems Immunity Research Institute (SIURI)
Subjects: R Medicine > RM Therapeutics. Pharmacology
R Medicine > RS Pharmacy and materia medica
Publisher: American Chemical Society
ISSN: 0022-2623
Last Modified: 05 Nov 2022 15:20
URI: https://orca.cardiff.ac.uk/id/eprint/22924

Citation Data

Cited 44 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item